The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MXCT | -57.06% | -4.91% | -0.99% | -6% |
| S&P | +18.33% | +108.18% | +15.79% | +114% |
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $8.51M | -18.4% |
| Gross Profit | $5.91M | -25.3% |
| Gross Margin | 69.45% | -6.4% |
| Market Cap | $231.78M | -43.4% |
| Market Cap / Employee | $2.03M | 0.0% |
| Employees | 114 | -20.3% |
| Net Income | -$12.36M | -31.8% |
| EBITDA | -$12.98M | -19.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $15.23M | -59.4% |
| Accounts Receivable | $5.75M | 25.6% |
| Inventory | 7.9 | -28.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $17.20M | -2.6% |
| Short Term Debt | $1.31M | 49.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -19.00% | -5.4% |
| Return On Invested Capital | -15.86% | 9.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$10.44M | -103.5% |
| Operating Free Cash Flow | -$9.85M | -103.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.92 | 2.05 | 1.40 | 1.16 | -35.72% |
| Price to Sales | 8.97 | 11.37 | 7.68 | 6.49 | -28.13% |
| Price to Tangible Book Value | 1.92 | 2.05 | 1.40 | 1.19 | -34.26% |
| Enterprise Value to EBITDA | -21.05 | -25.72 | -16.84 | -9.55 | -61.79% |
| Return on Equity | -16.0% | -18.7% | -19.6% | -21.7% | 41.78% |
| Total Debt | $18.32M | $18.03M | $18.82M | $18.51M | -0.11% |
MXCT earnings call for the period ending June 30, 2022.
MXCT earnings call for the period ending March 31, 2022.
MXCT earnings call for the period ending December 31, 2021.
MXCT earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
